Key Points
- Director Priscilla Hung sold 750 shares on April 30 at an average price of $155.64 for $116,730, reducing her direct stake by 18.74% to 3,253 shares; the sale was executed under a pre-arranged Rule 10b5-1 trading plan.
- Veeva beat quarterly estimates, reporting $2.06 EPS vs. $1.94 expected and revenue of $835.95M (up 16% YoY), and set FY2027 guidance around an $8.85 EPS range with Q1 2027 guidance of $2.13–2.14.
- The board approved a $2.0 billion share buyback (about 5.5% of shares), and recent catalysts — including inclusion in the S&P 500 and GenAI tailwinds — support momentum while analysts hold a consensus "Moderate Buy" with a $278.70 price target.
Veeva Systems Inc. (NYSE:VEEV - Get Free Report) Director Priscilla Hung sold 750 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $155.64, for a total value of $116,730.00. Following the sale, the director directly owned 3,253 shares in the company, valued at approximately $506,296.92. This trade represents a 18.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Priscilla Hung also recently made the following trade(s):
- On Friday, April 10th, Priscilla Hung sold 750 shares of Veeva Systems stock. The stock was sold at an average price of $153.50, for a total value of $115,125.00.
Veeva Systems Stock Performance
VEEV opened at $170.47 on Tuesday. The firm has a market cap of $27.84 billion, a P/E ratio of 31.51, a price-to-earnings-growth ratio of 0.77 and a beta of 0.92. Veeva Systems Inc. has a 52-week low of $148.05 and a 52-week high of $310.50. The business's fifty day moving average is $174.70 and its 200-day moving average is $216.26.
Veeva Systems (NYSE:VEEV - Get Free Report) last released its earnings results on Wednesday, March 4th. The technology company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. The company had revenue of $835.95 million for the quarter, compared to analyst estimates of $810.95 million. Veeva Systems had a return on equity of 13.80% and a net margin of 28.44%.Veeva Systems's quarterly revenue was up 16.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.74 EPS. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. On average, research analysts predict that Veeva Systems Inc. will post 6.41 earnings per share for the current fiscal year.
Veeva Systems announced that its board has initiated a stock repurchase program on Monday, January 5th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the technology company to repurchase up to 5.5% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's board believes its stock is undervalued.
Veeva Systems News Summary
Here are the key news stories impacting Veeva Systems this week:
- Positive Sentiment: S&P 500 addition and GC transition: Veeva’s inclusion in the S&P 500 and reported general counsel transition triggered strong buying interest, a primary reason for today’s upside as index funds and ETFs track the addition. Read More.
- Positive Sentiment: GenAI tailwinds: Multiple industry write-ups single out Veeva as a beneficiary of accelerating GenAI adoption in healthcare — reinforcing the growth story and investor appetite for software companies exposed to AI-driven workflow demand. Read More.
- Positive Sentiment: Analyst consensus / “Moderate Buy”: Broker surveys and coverage summaries show a constructive analyst stance (consensus “Moderate Buy”), which supports momentum following the S&P news and can attract additional buy-side interest. Read More.
- Neutral Sentiment: Brokerage commentary / ABR pieces: Media stories noting that brokers suggest buying Veeva may amplify demand, but several caution that average broker ratings can be optimistic — useful for sentiment but not definitive fundamental change. Read More.
- Neutral Sentiment: Coverage repeat: Additional write-ups (Zacks / industry pieces) reiterate the GenAI angle and the firm’s positioning — supportive background but largely confirmatory rather than news-driving. Read More.
- Negative Sentiment: Insider sale disclosed: Director Priscilla Hung sold 750 shares under a Rule 10b5-1 plan; while pre-arranged plans are common, insider selling can prompt some investors to reassess near-term conviction. Read More.
- Neutral Sentiment: Price action write-ups: Market observers noted a gap-up and heightened volume following the S&P inclusion — validates the move but doesn’t add new fundamentals. Read More.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on VEEV shares. TD Cowen reduced their target price on Veeva Systems from $380.00 to $300.00 and set a "buy" rating on the stock in a report on Thursday, March 5th. Piper Sandler dropped their price objective on Veeva Systems from $355.00 to $285.00 and set an "overweight" rating for the company in a research report on Thursday, March 5th. Weiss Ratings downgraded Veeva Systems from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, January 12th. JPMorgan Chase & Co. dropped their price objective on Veeva Systems from $330.00 to $296.00 and set an "overweight" rating for the company in a research report on Friday, February 20th. Finally, Wall Street Zen downgraded Veeva Systems from a "buy" rating to a "hold" rating in a research report on Sunday, March 22nd. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Veeva Systems has a consensus rating of "Moderate Buy" and a consensus price target of $278.70.
Check Out Our Latest Analysis on Veeva Systems
Hedge Funds Weigh In On Veeva Systems
Several large investors have recently bought and sold shares of the company. Linden Thomas Advisory Services LLC raised its position in Veeva Systems by 0.3% in the third quarter. Linden Thomas Advisory Services LLC now owns 12,444 shares of the technology company's stock valued at $3,707,000 after purchasing an additional 35 shares during the last quarter. Personal CFO Solutions LLC raised its position in Veeva Systems by 3.5% in the third quarter. Personal CFO Solutions LLC now owns 1,163 shares of the technology company's stock valued at $346,000 after purchasing an additional 39 shares during the last quarter. AFT Forsyth & Company Inc. raised its position in Veeva Systems by 4.2% in the third quarter. AFT Forsyth & Company Inc. now owns 984 shares of the technology company's stock valued at $293,000 after purchasing an additional 40 shares during the last quarter. Williams Jones Wealth Management LLC. raised its position in Veeva Systems by 0.4% in the third quarter. Williams Jones Wealth Management LLC. now owns 9,419 shares of the technology company's stock valued at $2,806,000 after purchasing an additional 40 shares during the last quarter. Finally, CIBC Asset Management Inc raised its position in Veeva Systems by 0.7% in the third quarter. CIBC Asset Management Inc now owns 6,821 shares of the technology company's stock valued at $2,032,000 after purchasing an additional 45 shares during the last quarter. 88.20% of the stock is currently owned by institutional investors.
Veeva Systems Company Profile
(
Get Free Report)
Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.
Veeva's product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
